Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

Alector, Inc.

ALECNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Oct 26, 2026Accepted Oct 26, 2026, 4:18 PM EDTFiling CIK 1653087Accession 0001346824-26-000247
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
Alector, Inc.
Company CIK
0001653087
Street
131 Oyster Point Blvd. Suite 600
City
South San Francisco
State / country code
CA
Postal code
94080

Statement details

Security class
Common Stock, $0.0001 par value per share
Event date
10/19/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
RA Capital Management, L.P.
Citizenship / organization
DE
Reporting person type
IA · PN
Aggregate amount owned
7,500,000.00
Percent of class
5.1
Sole voting power
0.00
Shared voting power
7,500,000.00
Sole dispositive power
0.00
Shared dispositive power
7,500,000.00

Reporting person 2

Name
Peter Kolchinsky
Citizenship / organization
X1
Reporting person type
HC · IN
Aggregate amount owned
7,500,000.00
Percent of class
5.1
Sole voting power
0.00
Shared voting power
7,500,000.00
Sole dispositive power
0.00
Shared dispositive power
7,500,000.00

Reporting person 3

Name
Rajeev Shah
Citizenship / organization
X1
Reporting person type
HC · IN
Aggregate amount owned
7,500,000.00
Percent of class
5.1
Sole voting power
0.00
Shared voting power
7,500,000.00
Sole dispositive power
0.00
Shared dispositive power
7,500,000.00

Reporting person 4

Name
RA Capital Healthcare Fund, L.P.
Citizenship / organization
DE
Reporting person type
PN
Aggregate amount owned
7,500,000.00
Percent of class
5.1
Sole voting power
0.00
Shared voting power
7,500,000.00
Sole dispositive power
0.00
Shared dispositive power
7,500,000.00

Item 1

Issuer

Alector, Inc.

Principal executive office address

131 Oyster Point Blvd. Suite 600, South San Francisco, CA, 94080.

Item 2

Citizenship

RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

Filing person

The names of the persons filing this report (collectively, the "Reporting Persons") are: RA Capital Management, L.P. ("RA Capital") Peter Kolchinsky ("Dr. Kolchinsky") Rajeev Shah ("Mr. Shah") RA Capital Healthcare Fund, L.P. (the "Fund") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Principal business or residence address

The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

Item 3

Not applicable indication

Y

Item 4

Percent of class

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Such percentage is based upon the sum of: (i) 111,656,919 shares of common stock outstanding as of July 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 6, 2026 and (ii) 36,600,000 shares of common stock issued in the Issuer's public offering of equity securities that closed on October 19, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 16, 2026.

Amount beneficially owned

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Fund directly holds 7,500,000 shares of common stock of the Issuer. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of common stock of the Issuer reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Sole voting power

Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

Shared voting power

Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

Sole dispositive power

Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

Shared dispositive power

Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit 99.1 Joint Filing Agreement

Signature 1

Reporting person
RA Capital Management, L.P.
Signed
/s/ Peter Kolchinsky
Title
By Peter Kolchinsky, Authorized Signatory
Date
10/26/2026

Signature 2

Reporting person
Peter Kolchinsky
Signed
/s/ Peter Kolchinsky
Title
Peter Kolchinsky
Date
10/26/2026

Signature 3

Reporting person
Rajeev Shah
Signed
/s/ Rajeev Shah
Title
Rajeev Shah
Date
10/26/2026

Signature 4

Reporting person
RA Capital Healthcare Fund, L.P.
Signed
/s/ Peter Kolchinsky
Title
By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date
10/26/2026

Filed exhibits

Company context

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Current securities

Recent company filings

  1. 10-Q filingNov 5, 2026
  2. Results of Operations and Financial ConditionNov 5, 2026
  3. 424B5 filingOct 16, 2026
  4. Entry into a Material Definitive Agreement · Other EventsOct 16, 2026
  5. FWP - filed by Alector, Inc. regarding Alector, Inc.Oct 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.